CDKL5 Deficiency Disorder
Conditions
Interventions
Part 1:
- Experimental (ZX008): ZX008 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses
maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]) with or without food.
- Placebo: Matching ZX008 placebo will be administered twice a
maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]). ZX008 will be administered twice a day (BID) in equally divided doses with or with
Sponsors
Soma Tadaharu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Subject has a confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene and a clinical diagnosis of CDD with epilepsy onset in the first year of life, plus motor and developmental delays. - Subject is male or female, aged 1 to 35 years, inclusive, as of the day of the Screening Visit. - Subject must have failed to achieve seizure control despite previous or current use of 2 or more AETs. - Subject is currently receiving at least 1 concomitant antiseizure treatment: antiseizure medication (ASM), vagus nerve stimulation (VNS), responsive neurostimulation (RNS), or ketogenic diet (KD). - All medications or interventions for epilepsy (including VNS, RNS, and KD) must be stable prior to screening and are expected to remain stable throughout the study. - At the Screening Visit, parent/caregiver reports that subject has >= 4 countable motor seizures(CMS) per week.
Exclusion criteria
Exclusion criteria: - Subject has a known hypersensitivity to fenfluramine or any of the excipients in the study drug. - Subject has a diagnosis of pulmonary arterial hypertension. - Subject has a clinically significant medical condition, including chronic obstructive pulmonary disease, interstitial lung disease, or portal hypertension, or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject. - Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke, severe ventricular arrhythmias, or clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, patent ductus arteriosus, and patent foramen ovale with reversal of shunt. (Note: Patent foramen ovale or a bicuspid aortic valve are not considered exclusionary). - Subject has moderate to severe hepatic impairment. - Subject has current eating disorder that suggests anorexia nervosa or bulimia. - Subject has a current or past history of glaucoma. - Subject is taking > 4 concomitant ASMs. Rescue medications are not included in the count. - Subject is receiving concomitant treatment with cannabidiol (CBD) other than Epidiolex/Epidyolex or is being actively treated with tetrahydrocannabinol (THC) or any marijuana product for any condition. - Subject is currently receiving another investigational product(s) or has received another investigational product within 30 days or within < 5 times the half-lives of the investigational product, whichever is longer, prior to the Screening Visit. - Subject has previously been treated with Fintepla (fenfluramine) prior to the Screening Visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The median percentage change from the Baseline Period (Baseline) in monthly (28 days) countable motor seizure frequency | — |
Countries
Austria, Belgium, France, Georgia, Germany, Ireland, Israel, Italy, Japan, Netherlands, Portugal, Spain, UAE, UK, USA
Contacts
Public ContactGlobal Clinical Science & Operation
UCB Japan Co., Ltd.
Outcome results
None listed